Potential role of CYP2D6 in the central nervous system

Xenobiotica

Volumn 43, Issue 11, 2013, Pages 973-984

  Cheng, Jie ^a   Zhen, Yueying ^a   Miksys, Sharon ^b   Beyoǧlu, Diren ^c   Krausz, Kristopher W ^a   Tyndale, Rachel F ^b   Yu, Aiming ^d   Idle, Jeffrey R ^c   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anxiety; Brain; CYP2D6; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANANDAMIDE; CARNITINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEOXYCYTIDINE; LEVACECARNINE; PANTOTHENIC ACID; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL CHROMOSOME; BLOOD SAMPLING; BRAIN HOMOGENATE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOWN REGULATION; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; SEROTONIN METABOLISM; SOUTHERN BLOTTING; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TRANSGENICS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CYTOCHROME P-450 CYP2D6; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; SEROTONIN; TISSUE DISTRIBUTION; TRANSGENES; URINE;

EID: 84885090957     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.791410     Document Type: Article

References (63)

1. Abel EL, Bilitzke PJ. (1990). A possible alarm substance in the forced swimming test. Physiol Behav 48:233-9
2. Allen JG, Brown AN, Marten TR. (1976). Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica 6:405-9
3. Allen JG, East PB, Francis RJ, Haigh JL. (1975). Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos 3:332-7
4. Berendsen HH, Broekkamp CL. (1990). Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667-73
5. Blakey GE, Lockton JA, Perrett J, et al. (2004). Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol 57:162-9
6. Bourre JM, Paturneau-Jouas MY, Daudu OL, Baumann NA. (1977). Lignoceric acid biosynthesis in the developing brain. Activities of mitochondrial acetyl-CoA-dependent synthesis and microsomal malonyl-CoA chain-elongating system in relation to myelination. Comparison between normal mouse and dysmyelinating mutants (quaking and jimpy). Eur J Biochem 72:41-7
7. Brockmoller J, Tzvetkov MV. (2008). Pharmacogenetics: Data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 64:133-57
8. Chen C, Gonzalez FJ, Idle Jr. (2007). LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 39:581-97
9. Corchero J, Granvil CP, Akiyama TE, et al. (2001). The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-7
10. Cryan JF, Valentino RJ, Lucki I. (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547-69
11. Deacon RM. (2006). Digging and marble burying in mice: Simple methods for in vivo identification of biological impacts. Nat Protoc 1: 122-4
12. Deuschl G, Elble RJ. (2000). The pathophysiology of essential tremor. Neurology 54:S14-20
13. Du W, Harvey JA. (1997). Harmaline-induced tremor and impairment of learning are both blocked by dizocilpine in the rabbit. Brain Res 745: 183-8
14. Dunder U, Valtonen P, Kelo E, Mononen I. (2010). Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. J Inherit Metab Dis 33: 611-17
15. Eiermann B, Edlund PO, Tjernberg A, et al. (1998). 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos 26:1096-101
16. Ferguson CS, Tyndale RF. (2011). Cytochrome P450 enzymes in the brain: Emerging evidence of biological significance. Trends Pharmacol Sci 32:708-14
17. Gan SH, Ismail R, Wan Adnan WA, et al. (2004). Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br J Clin Pharmacol 57:785-9
18. Gelboin HV, Krausz KW, Shou M, et al. (1997). A monoclonal antibody inhibitory to human P450 2D6: A paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 7:469-77
19. Gonzalez FJ. (2004). Cytochrome P450 humanised mice. Hum Genomics 1:300-6
20. Hawkins J, Hicks RA, Phillips N, Moore JD. (1978). Swimming rats and human depression. Nature 274:512-13
21. Hoffmann GF, Meier-Augenstein W, Stockler S, et al. (1993). Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis 16:648-69
22. Idle JR, Mahgoub A, Angelo MM, et al. (1979). The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol 7:257-66
23. Iwashima K, Yasui-Furukori N, Kaneda A, et al. (2007). No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol 64:96-9
24. Katoh M, Sawada T, Soeno Y, et al. (2007). In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428-37
25. Kema IP, de Vries EG, Muskiet FA. (2000). Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 747: 33-48
26. Kennedy EP, Borkenhagen LF, Smith SW. (1959). Possible metabolic functions of deoxycytidine diphosphate choline and deoxycytidine diphosphate ethanolamine. J Biol Chem 234:1998-2000
27. Kim E, Levy R, Pikalov A. (2007). Personalized treatment with atypical antipsychotic medications. Adv Ther 24:721-40
28. Kranz GS, Kasper S, Lanzenberger R. (2010). Reward and the serotonergic system. Neuroscience 166:1023-35
29. Li X, Morrow D, Witkin JM. (2006). Decreases in nestlet shredding of mice by serotonin uptake inhibitors: Comparison with marble burying. Life Sci 78:1933-9
30. Mahgoub A, Idle JR, Dring LG, et al. (1977). Polymorphic hydroxylation of Debrisoquine in man. Lancet 2:584-6
31. McLaughlin RJ, Hill MN, Bambico FR, et al. (2012). Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol 22: 664-71
32. Mehta H, Saravanan KS, Mohanakumar KP. (2003). Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav Brain Res 145:31-6
33. Micale V, Di Marzo V, Sulcova A, et al. (2012). Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol Ther 138:18-37
34. Miksys S, Rao Y, Hoffmann E, et al. (2002). Regional and cellular expression of CYP2D6 in human brain: Higher levels in alcoholics. J Neurochem 82:1376-87
35. Miksys S, Tyndale RF. (2006). Nicotine induces brain CYP enzymes: Relevance to Parkinson's disease. J Neural Transm Suppl 70:177-80
36. Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF. (2005). Human CYP2D6 and mouse CYP2Ds: Organ distribution in a humanized mouse model. Drug Metab Dispos 33:1495-502
37. Miwa H. (2007). Rodent models of tremor. Cerebellum 6:66-72
38. Nantel-Vivier A, Pihl RO, Young SN, et al. (2011). Serotonergic contribution to boys' behavioral regulation. Plos One 6:e20304
39. Njung'e K, Handley SL. (1991). Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63-7
40. Omura T, Sato R. (1964a). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-8
41. Omura T, Sato R. (1964b). The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-85
42. Rajadhyaksha A, Riviere M, Van Vooren P, et al. (1998). Assignment of AR1, transcription factor 20 (TCF20), to human chromosome 22q13.3 with somatic cell hybrids and in situ hybridization. Cytogenet Cell Genet 81:176-7
43. Rau T, Wohlleben G, Wuttke H, et al. (2004). CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants-A pilot study. Clin Pharmacol Ther 75:386-93
44. Rekdal C, Sjottem E, Johansen T. (2000). The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators. J Biol Chem 275:40288-300
45. Roberts RL, Luty SE, Mulder RT, et al. (2004). Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 127B:90-3
46. Sellers EM, Otton SV, Tyndale RF. (1997). The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. NIDA Res Monogr 173:6-26
47. Shinawi M, Gruener N, Lerner A. (1998). CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. Neurology 50:1869-71
48. Siegle I, Fritz P, Eckhardt K, et al. (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-45
49. Sridar C, Snider NT, Hollenberg PF. (2011). Anandamide oxidation by wild-Type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 39:782-8
50. Suzuki E, Kitao Y, Ono Y, et al. (2003). Cytochrome P450 2D6 polymorphism and character traits. Psychiatr Genet 13:111-13
51. Vandel P, Talon JM, Haffen E, Sechter D. (2007). Pharmacogenetics and drug therapy in psychiatry-The role of the CYP2D6 polymorphism. Curr Pharm Des 13:241-50
52. Vogelweid CM, Kier AB. (1988). A technique for the collection of cerebrospinal fluid from mice. Lab Anim Sci 38:91-2
53. Welsh JP, Chang B, Menaker ME, Aicher SA. (1998). Removal of the inferior olive abolishes myoclonic seizures associated with a loss of olivary serotonin. Neuroscience 82:879-97
54. Wijnen PA, Op den Buijsch RA, Drent M, et al. (2007). Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 26:211-19
55. Winter JC, Amorosi DJ, Rice KC, et al. (2011). Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-Type and CYP2D6- humanized mice. Pharmacol Biochem Behav 99:311-15
56. Wu C, Jiang XL, Shen HW, Yu AM. (2009). Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 78:617-24
57. Yamazaki M, Tanaka C, Takaori S. (1979). Significance of central noradrenergic system on harmaline induced tremor. Pharmacol Biochem Behav 10:421-7
58. Yang SY, He XY, Schulz H. (1987). Fatty acid oxidation in rat brain is limited by the low activity of 3-ketoacyl-coenzyme A thiolase. J Biol Chem 262:13027-32
59. Yu AM, Idle JR, Byrd LG, et al. (2003a). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173-81
60. Yu AM, Idle JR, Gonzalez FJ. (2004). Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metab Rev 36:243-77
61. Yu AM, Idle JR, Herraiz T, et al. (2003b). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-19
62. Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37
63. Zarringhalam K, Zhang L, Kiebish MA, et al. (2012). Statistical analysis of the processes controlling choline and ethanolamine glycerophospholipid molecular species composition. PLoS One 7:e37293